AbstractObjectivesNeoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients with pancreatic cancer. This study was conducted to evaluate the Virginia Mason Protocol (5‐fluorouracil, cisplatin, interferon‐α and radiation) given in the neoadjuvant setting for the treatment of locally advanced pancreatic cancer.MethodsA Phase II pilot study evaluating interferon‐based neoadjuvant CRT in patients with locally advanced pancreatic cancer was performed.ResultsA total of 23 patients were enrolled. The mean age of the patients was 58.6 years. Of the 23 patients, seven (30.4%) completed all treatments. In the remaining 16 (69.6%) patients, treatment was interrupted as a result of toxicity. The most commonly reported effects of t...
The survival of patients with pancreatic cancer is dismal: tumor's resection is possible in only 10-...
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths among men and women, b...
Pancreatic ductal adenocarcinoma is a highly aggressive malignancy with a poor prognosis. Effective ...
AbstractObjectivesNeoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients wi...
BACKGROUND: Pancreatic ductal adenocarcinoma is a largely incurable cancer. Surgical resection remai...
Pancreatic cancer (PC) is the fourth cause of cancer death in Western countries, the only chance for...
Context Pancreatic cancer resection represents the only chance of cure but it can be performed only ...
BACKGROUND: Surgical resection is the only curative treatment for pancreatic cancer, but surgical ou...
Pancreatic cancer has an extremely poor prognosis, only a small minority of patients undergo a resec...
Abstract Introduction To evaluate efficacy and secondary resectability in patients with locally adva...
Pancreatic cancer has an extremely poor prognosis and prolonged survival is achieved only by resecti...
BACKGROUND AND PURPOSE: Neoadjuvant chemoradiation could improve survival in patients with pancreati...
Introduction: We sought to investigate the efficacy of neoadjuvant chemotherapy (CT) followed by che...
Pancreatic cancer is the third most common cause of cancer deaths in the United States. Surgical res...
none10noObjective The objective of the study is to evaluate the usefulness of neoadjuvant chemoradi...
The survival of patients with pancreatic cancer is dismal: tumor's resection is possible in only 10-...
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths among men and women, b...
Pancreatic ductal adenocarcinoma is a highly aggressive malignancy with a poor prognosis. Effective ...
AbstractObjectivesNeoadjuvant chemoradiotherapy (CRT) is a viable treatment strategy for patients wi...
BACKGROUND: Pancreatic ductal adenocarcinoma is a largely incurable cancer. Surgical resection remai...
Pancreatic cancer (PC) is the fourth cause of cancer death in Western countries, the only chance for...
Context Pancreatic cancer resection represents the only chance of cure but it can be performed only ...
BACKGROUND: Surgical resection is the only curative treatment for pancreatic cancer, but surgical ou...
Pancreatic cancer has an extremely poor prognosis, only a small minority of patients undergo a resec...
Abstract Introduction To evaluate efficacy and secondary resectability in patients with locally adva...
Pancreatic cancer has an extremely poor prognosis and prolonged survival is achieved only by resecti...
BACKGROUND AND PURPOSE: Neoadjuvant chemoradiation could improve survival in patients with pancreati...
Introduction: We sought to investigate the efficacy of neoadjuvant chemotherapy (CT) followed by che...
Pancreatic cancer is the third most common cause of cancer deaths in the United States. Surgical res...
none10noObjective The objective of the study is to evaluate the usefulness of neoadjuvant chemoradi...
The survival of patients with pancreatic cancer is dismal: tumor's resection is possible in only 10-...
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths among men and women, b...
Pancreatic ductal adenocarcinoma is a highly aggressive malignancy with a poor prognosis. Effective ...